Gemase

Country of origin: Russia

Pharm-Group: Fibrinolytic agents

Manufacturers: Russian Cardiology Research and Production Complex of the Ministry of Health of the Russian Federation (Russia)

International name: Prourokinase

Synonyms: Prourokinase recombinant

Dosage forms: lyophilisate for the preparation of solution for injection 5000IU

Composition: Active substance - recombinant prourokinase.

Indications for use: RPU is used as a thrombolytic agent for occlusion of coronary vessels (acute myocardial infarction).

Contraindications: Increased individual sensitivity to the drug. Diseases manifested by increased bleeding (hemorrhagic diathesis - hemophilia, thrombocytopenia, etc.) or conditions with a high risk of bleeding: gastrointestinal bleeding up to 4 weeks old; extensive surgery or extensive trauma less than 4 weeks old; intracranial or intraspinal interventions up to 8 weeks old; head injury less than 4 weeks old; resuscitation efforts requiring intense chest compressions, including cardiopulmonary resuscitation for more than 10 minutes, associated with this case; liver diseases with severe disruption of the hemostasis system; puncture of non-compressible vessels (v. subclavia); diabetic hemorrhagic retinopathy; previous hemorrhagic stroke; systolic blood pressure ≥ 180 mmHg. or diastolic blood pressure ≥ 110 mmHg; cardiogenic shock (class IV circulatory failure according to Killip); suspected aortic dissection; septic endocarditis; pregnancy.

Side effects: Allergic reactions, arterial hypotension and bleeding of varying severity (from puncture sites and surgical incisions) are possible. With the development of hypotension - systolic blood pressure less than 90 mmHg. and bradycardia - heart rate less than 50 beats/min. It is recommended to suspend the administration of the drug until blood pressure and heart rate normalize.

Interaction: The risk of bleeding may increase when used together with acetylsalicylic acid or other antiplatelet drugs, as well as heparin and indirect anticoagulants.

Overdose: An overdose of the drug is usually manifested by hemorrhagic complications. Minor bleeding can be controlled without stopping the administration of prourokinase by temporarily stopping the heparin infusion with additional monitoring of the aPTT (activated partial thromboplastin time).

Special instructions: Used in stationary conditions.